The IPO Buzz: TRex Bio (TRXB Proposed) Sets Terms for $125 Million IPO
TRex Bio (TRXB Proposed), an Eli Lilly-backed biotech, unveiled the terms for its $125 million IPO early today: 8.33 million shares at a price range of $14.00 to $16.00 to raise $124.95 million, if priced at the $15.00 mid-point of its range, according to its S-1 filing dated Oct. 5, 2026. This is a NASDAQ listing. (Please see the IPO Calendar for the pricing date.) At pricing, TRex Bio woul..
Read more October 5, 2026IPO Calendar
| Company | Symbol proposed | Shares (Millions) | Est. $ Volume | Expected to Trade | SCOOP Rating | Rating Change |
|---|---|---|---|---|---|---|
| AfterNext Acquisition I Corp. | AFNXU | 10.0 | $ 100.0 mil | 10/7/2026 Wednesday | S/O | S/O |
| Retension Pharmaceuticals | RTSN | 3.3 | $ 39.6 mil | 10/9/2026 Friday | S/O | S/O |
| TRex Bio, Inc. | TRXB | 8.3 | $ 125.0 mil | 10/9/2026 Friday | S/O | S/O |
Last 100 IPOs - October 4, 2026
| Number of IPOs priced : | 100 |
| Number Up: | 40 |
| Number Down: | 59 |
| Number Unchanged: | 1 |
| Percentage Change From Issue Price: | 0.04% |
| Percentage Change for The Nasdaq Composite | 35.22% |
2026 IPO Scorecard - October 4, 2026
| Number of IPOs priced (Excluding 151 units) : | 125 |
| Number Up: | 47 |
| Number Down: | 77 |
| Number Unchanged: | 1 |
| Total Return From Issue Price: | -0.82% |
| The Nasdaq Composite Index YTD % Change | 35.22% |